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Introduction
============

The isolation of cyclopamine (**1**, [Fig. 1](#F1){ref-type="fig"}) nearly 50 years ago followed by the determination of its biological target and pharmacological profile has drawn considerable interest from research groups in biology, chemistry and medicine \[[@R1]--[@R4]\]. As the first identified hedgehog signaling inhibitor, cyclopamine exerts its anticancer activity through a novel mechanism of action, which manifests itself in its remarkable activity against several types of human cancer, including medulloblastoma, basal cell carcinoma, and rhabdomyosarcoma \[[@R5]--[@R10]\]. The impressive biological activity combined with a unique molecular architecture and the synthetic challenge it poses already let to the first synthesis of cyclopamine by this laboratory employing C--H-functionalization logic \[[@R11]\]. In addition, the rational design and chemical synthesis of several analogs and derivatives by this \[[@R12]--[@R13]\] and other groups \[[@R14]--[@R17]\] have been disclosed. Here, we report the synthesis of a carbacyclopamine analog (**2**, [Fig. 1](#F1){ref-type="fig"}), an analog of the natural product with an all-carbon E-ring and a pyridine F-ring.
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Cyclopamine inhibits the 7-transmembrane protein smoothened from converting into its active form \[[@R18]--[@R19]\]. Without active smoothened, protein kinases like PKA, GSK3β, and CK1ε phosphorylate the transcription factors Gli2 and Gli3, thereby creating binding sites for the adapter protein β-TrCP \[[@R20]\]. The Gli family of transcription factors acts as an effector of the hedgehog signaling pathway and thus, is associated with a wide array of physiological effects, including cell fate determination, proliferation and patterning. The so-formed Gli/β-TrCP complex becomes subject to ubiquitinylation, mediated by the Cul1-based E3 ligase. Eventually, this results in partial proteosomal degradation to form Gli3-R \[[@R21]\], or in the case of Gli2 \[[@R22]--[@R23]\], in complete degradation. In addition, the Gli3-R factor acts as a transcription inhibitor of hedgehog-response genes \[[@R10]\].

As part of our continuing work on acid-stable cyclopamine analogs \[[@R12]--[@R13]\] we have now focused on the role of the allylic ether oxygen in the acid-mediated E-ring cleavage and decomposition of cyclopamine \[[@R24]\]. We envisioned that its replacement by a methylene group would create an acid-stable cyclopamine analog that still exhibits similar inhibitory activity on hedgehog-signaling. For the sake of brevity of the overall synthetic sequence we defined carbacyclopamine analog **2** (see [Fig. 1](#F1){ref-type="fig"}) as our primary target.

Results and Discussion
======================

A retrosynthetic analysis identified diazo compound **3** as a key intermediate in the synthesis of **2** (see [Scheme 1](#C1){ref-type="fig"}). We envisioned a rhodium-catalyzed C--H-insertion into the C17--H bond to occur with a high degree of selectivity (both regio- and stereoselectivity) to form the all-carbon E-ring (for its structure see **11**, [Scheme 2](#C2){ref-type="fig"}). Furthermore, a Wagner--Meerwein rearrangement was thought to establish the C-*nor*-D-*homo* steroid system, and a gold-catalyzed amination/annulation/aromatization sequence was planned to install the pyridine F-ring. Diazo compound **3** originates from diene **4** through standard transformations, the latter being accessible from commercially available and inexpensive dehydroepiandrosterone (**5**) by the means of a copper-mediated C--H hydroxylation in the 12-position and a palladium-catalyzed coupling of methyl acrylate to an activated enol ether in the 17-position.
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In synthetic direction ([Scheme 2](#C2){ref-type="fig"}), dehydroepiandrosterone (**5**) was protected as its tetrahydropyranyl ether (3,4-dihydro-2*H*-pyran, cat. pyridinium *para*-toluenesulfonate, CH~2~Cl~2~, 25 °C, quantiative, inconsequential mixture of diastereoisomers), and the C17 carbonyl group was transformed into its 2-picolylimine (2-picolylamine, cat. *para*-toluenesulfonic acid, toluene, 111 °C, 92% yield). Subjecting the latter to modified Schönecker conditions (\[Cu(MeCN)~4~\]PF~6~, O~2~, acetone, 25 °C) \[[@R25]--[@R27]\], gave, after acidic work-up (AcOH/MeOH, 1:1, 90 °C), diol **6** in 46% yield as the only isolable product. Protection of the newly installed 12β-hydroxy group as a triethylsilyl ether via the bis-protected intermediate (not shown, triethylsilyl trifluoromethanesulfonate, 2,6-lutidine, CH~2~Cl~2~, 0 °C; then HF·pyridine, THF, 0 °C, 67% yield for the two steps) \[[@R28]\] gave hydroxy ketone **7**.

The remaining homoallylic alcohol was then masked as an *i*-steroid \[[@R29]--[@R30]\] (*para*-toluenesulfonyl chloride, cat. 4-dimethylaminopyridine, pyridine, 25 °C; then KOAc, MeOH, 64 °C, 85% yield for the two steps) to give **8**. Generation of an enol triflate from the carbonyl group in **8** (potassium hexamethyldisilazide, phenyl bis-triflimide, THF, −20 → −10 °C, 85% yield) set stage for a Heck-reaction with methyl acrylate (cat. Pd(OAc)~2~, cat. PPh~3~, Et~3~N, DMF, 70 °C, 64% yield). The hydrogenation of the so-obtained diene **4** (for its structure see [Scheme 1](#C1){ref-type="fig"}) proceeded smoothly (H~2~, cat. Pd/C, MeOH, 25 °C, 82% yield) under concomitant removal of the triethylsilyl ether \[[@R31]\] in 12-position to give methyl ester **9** as a single diastereoisomer. At this point, extensive experimentation suggested a change of protecting groups to enable the pending C--H insertion reaction at C17.

Therefore, the *i*-steroid was reverted to the homoallylic alcohol (cat. *para*-toluenesulfonic acid, 1,4-dioxane/H~2~O, 10:1, 65 °C), the methyl ester was hydrolyzed under basic conditions (LiOH, THF/H~2~O, 1:1, 68% yield for the two steps), and the alcohol moieties were protected as formyl esters (formic acid, 50 °C, 85% yield) to give key intermediate **10**.

Employing the formyl protecting groups \[[@R32]\], diazoketone **3** (for its structure see [Scheme 1](#C1){ref-type="fig"}) was readily obtained from acid **10** via the corresponding acid chloride (oxalyl chloride, CH~2~Cl~2~, 25 °C; then diazomethane, THF, 25 °C, 85% yield for the two steps) \[[@R33]\]. The anticipated C--H insertion then proceeded uneventfully under oxygen-free conditions (cat. Rh~2~(OAc)~4~, CH~2~Cl~2~, 41 °C) \[[@R34]--[@R35]\] to give cyclopentanone **11** in 52% yield as a single isomer. Removal of the formyl ester protecting groups (LiOH, THF/H~2~O, 1:1, 30 °C, 94% yield) and selective protection of the 3-hydroxy group as a *tert*-butyldimethylsilyl ether (*tert*-butyldimethylsilyl chloride, imidazole, DMF, 25 °C, 95% yield) furnished alcohol **12**.

Treatment of the latter under our previously reported conditions \[[@R36]\] (Comins' reagent, 4-dimethylaminopyridine, toluene, 111 °C) gave an inseparable mixture of the rearranged olefin products, with the desired *endo*-product **13** as the major constituent (89% combined yield, *endo*-product **13**:*exo*-product **14**, 4:1). Isolation of desired product **13** by chromatography was then achieved after selective hydrogenation of only the exocyclic olefin in **14** (H~2~, cat. Rh/C, EtOAc, 25 °C, structure of hydrogenation product not shown) employing the mixture of the isomers **13** and **14** from the previous step.

Finally, a gold-catalyzed amination/annulation/aromatization sequence (propargylamine, cat. Na\[AuCl~4~\]·2H~2~O, EtOH, 100 °C) \[[@R37]--[@R38]\] furnished, after removal of the *tert*-butyldimethylsilyl ether (tetrabutylammonium fluoride, THF, 25 °C), carbacyclopamine analog **2** in 36% overall yield for the two steps \[[@R39]\].

Carbacyclopamine analog **2** was then tested for its stability towards acid. Therefore, **2** was treated with a mixture of aqueous HCl/THF (pH of approx. 0.3) for 1 h and ^1^H NMR spectra were recorded before and afterwards. While at this pH natural cyclopamine (**1**) was shown to decompose rapidly \[[@R12]\], carbacyclopamine analog **2** showed no signs of decomposition. This result was in full agreement with our initial considerations.

To determine the ability of carbacyclopamine analog **2** to inhibit Gli1-dependent luciferase expression, we employed Shh-LIGHTII cells, a clonal mouse fibroblast cell line which stably incorporates a Gli-dependent firefly luciferase reporter and a constitutive *Renilla* luciferase reporter \[[@R18]\]. The analog was tested in a concentration range from 0.01 μM to 100 μM but showed no activity (data not shown).

Conclusion
==========

We have reported the synthesis of a new, acid stable cyclopamine analog. The implementation of C--H-functionalization logic in the synthetic planning and further metal-catalyzed transformations allows for a fast access to carbocyclopamine analog **2**. At the same time, these investigations strongly suggest the role the ether oxygen plays in the acid-catalyzed decomposition of cyclopamine. This study may find further application in the rational design of new hedgehog inhibitors based on lead structure **2**. Future work will focus on the synthesis of carbacyclopamine analogs with a piperidine F-ring and their biological investigation.

Supporting Information
======================

###### 

Experimental procedures, characterization data, and copies of ^1^H and ^13^C NMR spectra for new compounds.

We thank Dr. Lothar Hennig, Universität Leipzig, for his help with recording and interpreting the 2D NMR spectra.
